A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC.
This is a study exploring cemiplimab, an immunotherapy medicine, before surgery for treating resectable lung cancer, liver cancer, and head and neck cancer in multiple groups.
an immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing. |
resectable lung cancer: Some patients have a tumor that is “resectable,” which means that it is able to be removed with surgery. |
For more information about the trial, click the link below:
Clinical Trial Site: Sinai
To see all available clinical trials click here.
Comments